CRB-701
Nectin-4 expressing solid tumors (e.g., HNSCC, Cervical Cancer, mUC)
Phase 1Dose optimization
Key Facts
Indication
Nectin-4 expressing solid tumors (e.g., HNSCC, Cervical Cancer, mUC)
Phase
Phase 1
Status
Dose optimization
Company
About Corbus Pharmaceuticals
Founded in 2009, Corbus Pharmaceuticals is a publicly-traded company focused on advancing targeted treatments for oncology and metabolic diseases. Its strategy leverages deep biological insight into mechanisms like Nectin-4 in cancer and peripheral CB1 receptors in obesity. The company has progressed its lead oncology asset, CRB-701, into dose optimization studies and recently reported positive Phase 1a safety data for its obesity candidate, CRB-913, positioning it for continued clinical development.
View full company profile